Edwards Lifesciences Corporation (EW)

Market Cap	48.77B
Revenue (ttm)	5.88B
Net Income (ttm)	1.37B
Shares Out	580.30M
EPS (ttm)	2.33
PE Ratio	36.76
Forward PE	30.64
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,332,833
Open	85.05
Previous Close	84.74
Day's Range	84.03 - 85.66
52-Week Range	65.94 - 87.21
Beta	0.97
Analysts	Buy
Price Target	92.35 (+9.89%)
Earnings Date	Oct 30, 2025

About EW

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solution...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Mar 27, 2000
• Employees: 15,800
• Stock Exchange: NYSE
• Ticker Symbol: EW
• Website: https://www.edwards.com

Financial Performance

In 2024, Edwards Lifesciences's revenue was $5.44 billion, an increase of 8.57% compared to the previous year's $5.01 billion. Earnings were $4.17 billion, an increase of 197.68%.

Analyst Summary

According to 19 analysts, the average rating for EW stock is "Buy." The 12-month stock price target is $92.35, which is an increase of 9.89% from the latest price.

Price Target

$92.35

(9.89% upside)

Analyst Consensus: Buy